Eisai Hopes To Resume Trials On New Alzheimer's Drug (Japan)
This article was originally published in PharmAsia News
Executive Summary
Eisai reports it will resume clinical trials this fiscal year on E2012, the planned-for successor to its Alzheimer's drug Aricept. Eisai began phase I trials on E2012 in 2006 in the U.S., but suspended the trials earlier this year after concomitant trials in rats indicated that E2012 could cause clouding of the eyes. The drug firm has since done experiments with rats and discovered that the eye problem developed because E2012 caused blood cholesterol levels to fall too far. The tests also found that using E2012 in a lower dose kept the blood cholesterol levels from declining too much. Eisai has talked with the U.S. Food and Drug Administration and hopes to resume clinical trials before the end of the current fiscal year after finding a blood marker that can be used to monitor safety. (Click here for more - May Require Paid Subscription
You may also be interested in...
Rethinking Alzheimer's: Mapping Out an Approval Process
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.